Home  >  Press Releases  >  Most Recent
Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
November 1, 2012
Australian horse owners who are battling against the deadly Hendra virus received an important boost today with the introduction of Equivac® HeV vaccine. The Equivac® HeV vaccine will be available for use under permit by accredited veterinarians thanks to an international public-private partnership created to make this important new vaccine accessible. The vaccine, launched by Pfizer Animal Health, will help prevent the spread of the Hendra virus by breaking the cycle of transmission that puts humans at risk. Hendra virus has claimed the lives of four people and 81 horses since 1994.i With no known cure for Hendra virus, the Equivac HeV vaccine is positioned to become the most effective defence against this emerging infectious disease. “As a veterinarian, I have seen firsthand how Hendra has created difficult working conditions for my colleagues and any Australian who works with horses,” said Dr. Deborah Middleton, veterinary pathologist and leader of the Hendra virus vaccine project ...
October 3, 2012
Pfizer Animal Health announces the launch of Poulvac E coli, the first spray vaccine against avian pathogenic Escherichia coli (APEC) for the poultry industry to be approved in the European Union. This new vaccine is based on a European E. coli isolate, and has been shown to provide a broad protection against field infections found in the region. It can be administered from one day of age, and studies have shown that it generates a strong immune response that reduces mortality for up to 12 weeks1-4. The vaccine has a zero-day withdrawal period. Revaccination depending on local field pressure and risk assessment can be considered in consultation with a veterinarian. This vaccine represents the first effective vaccine that can be administered en masse to birds to prevent often devastating infections with E. coli in poultry. It represents an innovation for the market as the first ever product to be administered by coarse spray. The new product provides a new preventative option for both ...
August 13, 2012
NEW YORK-Pfizer Inc. (NYSE: PFE) today announced that its subsidiary, Zoetis™ Inc. (zō-EH-tis), filed a registration statement with the U.S. Securities and Exchange Commission for a potential initial public offering (IPO) of Class A common stock. The offering is expected to represent an ownership stake of up to 20 percent. Prior to completion of the offering, which is targeted for the first half of 2013, Pfizer will transfer its animal health business to Zoetis. The number of shares to be offered and the price range for the offering have not yet been determined. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any ...
July 25, 2012
VANCOUVER, British Columbia-Data to be presented this week at the 7th World Congress of Veterinary Dermatology (WCVD) Meeting 2012 will report new insights into the disease pathways involved in allergic conditions in dogs, Pfizer Animal Health announced today. Researchers with Pfizer Animal Health’s Global Therapeutic Research Group have, for the first time, identified a potential role for the cytokine IL-31 in triggering itch responses in dogs. The research indicates that canine IL-31 (cIL-31) triggers the activation of the JAK/STAT signal transduction pathway on cells that express receptors for IL-31 and may interact with IL-31 receptors on neurons to initiate a signal that travels along the nerve to the brain and results in itching in dogs. “This work conducted by the research team demonstrates that the pathways involved in itchy conditions in dogs are similar to those recognized in the last decade in human dermatologic conditions such as atopic dermatitis, psoriasis and allergic ...
July 25, 2012
VANCOUVER, British Columbia-Pfizer Animal Health will present data from discovery studies validating specific pathways of allergic skin disease in dogs and studies evaluating novel molecules targeting these pathways at the 7th World Congress of Veterinary Dermatology (WCVD) Meeting 2012 in Vancouver, British Columbia, from July 24–28. Approximately six presentations related to Pfizer’s research and development program in veterinary dermatology are scheduled. “Pfizer Animal Health is committed to advancing research in veterinary dermatology,” said Candace Sousa, DVM, DABVP, DACVD, a dermatologist and senior veterinary specialist with the Pfizer Animal Health Veterinary Specialty Team. “We believe new data presented at WCVD will enable veterinarians to think about the pathobiology of allergic skin diseases in different ways. These studies provide evidence that will guide research into new therapies that target these disease pathways, which are involved in a number of veterinary ...
July 23, 2012
MADISON, N.J.-Pfizer Animal Health (PAH) has launched two educational web sites to communicate advancements in veterinary dermatology and help improve the discussions between veterinarians and pet owners about allergic skin conditions. The two sites—www.mypetitches.com and www.itchcycle.com —bring visitors the latest research and news from the dermatological community and highlight new information about PAH’s portfolio of products for allergic skin conditions. Candace Sousa, DVM, DABVP, DACVD, a dermatologist and senior veterinary specialist with the Pfizer Animal Health Veterinary Specialty Team, said the launch of the two sites represents PAH’s ongoing commitment to advancing veterinary dermatology—from providing educational tools, programs and websites to researching and developing new molecules and treatment pathways. “Every day in clinics and hospitals across the country, a significant portion of a veterinarian’s schedule is spent treating pets with allergic skin conditions and ...
June 7, 2012
NEW YORK-Pfizer Inc. (NYSE: PFE) today announced the next steps in the strategic alternatives review process for the company's Animal Health business. Preparations are underway to file a registration statement in the U.S. for a potential initial public offering (IPO) of a minority ownership stake in the new company. Pfizer expects to provide details regarding the proposed transaction as part of its 2012 second quarter earnings announcement. Animal Health will continue to be treated as a continuing operation for Pfizer’s financial reporting purposes. The name of the new standalone company will be Zoetis™ (zō-EH-tis). “Pfizer Animal Health is a dynamic business with strong fundamentals, an expanding and loyal direct customer base and a proven management team,” said Ian Read, chairman and chief executive officer, Pfizer. “We are on track to create a standalone Animal Health company by our previously stated target of July 2013. Our focus continues to be on taking the actions that will ...
April 19, 2012
PARIS, France-The famous Auzoux Horse, one of the first veterinary teaching aids of its kind, has been restored to its former glory thanks to a €50,000 grant from Pfizer Animal Health. The papier-mâché model dates back to 1846 and was initially created to allow veterinary students to mimic a dissection without having to use an actual cadaver, an unpleasant and dangerous choice in an era when it was not uncommon for people to die of complications from a simple cut. It is labelled and can be completely taken apart, offering a hyper-realistic, precisely detailed overview of a horse’s anatomy, comparable to what one might learn through dissection. When the first prototype was created in 1844 by physician Louis Auzoux, it was a revolutionary teaching aid for veterinary students. The restored model is one of the main attractions of the Fragonard Museum at the Alfort National Veterinary School [École nationale vétérinaire d’Alfort (ENVA)], which has earned the prestigious ‘Musée de France’ ...
April 13, 2012
PARIS, France-Four European academic research groups, together with Pfizer Animal Health, have forged a new research consortium to combat uterine disease - a problem that costs the EU dairy industry about €1.4billion annually. Called the IPUD research project (Integrated systems approach for Preventing Uterine Disease in dairy cattle), the collaboration involves academic research groups at Swansea University, the University of Glasgow in the UK, the University of Veterinary Medicine of Hannover in Germany and INRA in France, and Pfizer Animal Health as industry partner. The partnership, valued at €3.2 million, includes a grant awarded to the consortium by EMIDA ERA-Net – the European Commission’s body to improve science on emerging and major infectious diseases in livestock. “The objective of the consortium approach is to bring together the best minds in the research institutes around Europe to address one of the most costly and neglected cattle diseases,” said Peter Jeffries, Group ...
April 11, 2012
Arkansas University Students Win Poultry Industry Award RALEIGH, N.C.-Poultry science students at the University of Arkansas have been awarded a $3,000 grant for their initiative which aims to improve the public’s understanding of the poultry industry. The award is courtesy of Reach Teach Learn―a Pfizer Animal Health Global Poultry project―which invited agriculture students across the U.S. to demonstrate how they could open a dialogue with consumers and enhance the perception of the poultry industry and its products. Through an online video submission, the University of Arkansas Poultry Science Club detailed their Poultry Education Program (PEeP), aimed at enlightening young people who have little experience with agriculture or knowledge about where their food comes from. “In a practical program that has already proved successful, we lead children and young people through a series of displays and hands-on activities such as identifying feed ingredients, classifying eggs according to ...
March 29, 2012
LONDON, England-The Chinese Veterinary Medical Association (CVMA) and the International Veterinary Collaboration for China (IVCC), a consortium of leading veterinary medical schools in the United States and United Kingdom and Pfizer Animal Health, announced the signing of a memorandum of understanding through which the CVMA will collaborate with the IVCC to advance veterinary medical education and animal health in mainland China. “I am confident our collaboration with the IVCC will make possible scientific exchange of best practices in veterinary medicine between the professional communities in China, the United States and United Kingdom,” said Dr Jia Youlin, President of the CVMA. “This increased access and sharing of knowledge and ideas will enrich and strengthen veterinary education in China especially at the undergraduate education level.” The CVMA, founded in 2009, is the first organisation representing the veterinary profession in China. It is devoted to introducing ...
February 27, 2012
MADISON, N.J.-Fostera™ PRRS*, a modified-live vaccine for growing pigs from Pfizer Animal Health, brings a new high standard of innovation to the costly battle against porcine reproductive and respiratory syndrome (PRRS) respiratory disease. Demonstrating its commitment to high standards, Pfizer Animal Health's research and development team made a significant breakthrough. They created unique cell lines that were able to express a newly discovered key receptor protein for the PRRS virus (PRRSv). This innovative thinking was pivotal in bringing Fostera PRRS to the pork industry. "With more than half of weaning-age PRRSv-negative pigs becoming infected before going to market1, this innovative vaccine option helps growing pigs defend themselves against a PRRSv challenge," says Steve Sornsen, DVM, MS, senior director, Veterinary Business Solutions at Pfizer Animal Health. A challenge study2 demonstrated that Fostera PRRS, which is the first and only PRRSv vaccine to earn the label claim ...
January 27, 2012
Dozulé, Normandy, France-Pfizer Animal Health and The Hippolia Foundation announced today the formation of a strategic partnership to advance equine health through research and educational programmes. The Hippolia Foundation – a network of leading French equine institutions together with international partners – will collaborate with Pfizer to accelerate advancement in innovation on the diagnosis, treatment and prevention of equine disease. The Hippolia partner organisations and Pfizer are initially investing more than $5 million over three years. “This is an excellent example of a public/private initiative to advance our scientific knowledge and improve animal health and welfare,” said Pierre Lekeux, President, The Hippolia Foundation. The two principal areas of collaboration to be developed between Pfizer and The Hippolia Foundation will focus on respiratory disorders, and on infectious diseases. “This is a particularly synergistic partnership,” said Alejandro Bernal, Area ...
January 25, 2012
DURHAM, N.C.-Pfizer Animal Health Global Poultry’s new in ovo vaccination device, which was officially unveiled at IPE, could help improve operations at smaller hatcheries, according to one of the device’s trial participants. Marciano Régis Tonus, agribusiness director of Frango Seva, in Pato Branco, Brazil, spent a month trialling the new Embrex® Inovoject® m, a semi-automated device designed specifically for hatcheries that do not have the floor space or throughput to accommodate one of the larger, fully automated Embrex Inovoject devices. Processing greater than 800,000 eggs throughout the trial, Mr Tonus is pleased with the results. “I believe that all hatcheries handling about the same number of eggs as this hatchery would be able to use a machine like Inovoject m. It’s small, easy to use and it’s simple.” Mr Tonus explained that the company had been using subcutaneous vaccination before trialling the in ovo technology. “The most common problem we have with subcutaneous ...